argenx (NASDAQ:ARGX) had its target price decreased by HC Wainwright from $272.00 to $265.00 in a research report released on Friday morning, Analyst Ratings Network reports. HC Wainwright currently has a neutral rating on the stock.
A number of other research analysts have also recently issued reports on the stock. Zacks Investment Research cut shares of argenx from a hold rating to a sell rating in a research note on Thursday, October 8th. Morgan Stanley boosted their price target on argenx from $258.00 to $281.00 and gave the stock an overweight rating in a report on Monday, August 10th. Bank of America raised their price objective on argenx from $265.00 to $298.00 and gave the company a buy rating in a research note on Tuesday, October 6th. Raymond James began coverage on argenx in a research note on Monday, August 24th. They set an outperform rating and a $257.00 target price for the company. Finally, Robert W. Baird lifted their price target on shares of argenx from $265.00 to $275.00 and gave the company an outperform rating in a report on Tuesday, October 6th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and sixteen have assigned a buy rating to the company. The stock presently has an average rating of Buy and a consensus price target of $249.59.
ARGX opened at $249.42 on Friday. argenx has a 52-week low of $103.75 and a 52-week high of $284.00. The firm has a market cap of $11.72 billion, a P/E ratio of -52.73 and a beta of 1.00. The business’s fifty day moving average is $252.51 and its 200-day moving average is $216.62.
Several large investors have recently bought and sold shares of the company. Oppenheimer Asset Management Inc. increased its position in shares of argenx by 6.0% during the second quarter. Oppenheimer Asset Management Inc. now owns 1,381 shares of the company’s stock worth $311,000 after buying an additional 78 shares during the period. Vestmark Advisory Solutions Inc. grew its holdings in argenx by 4.1% during the 3rd quarter. Vestmark Advisory Solutions Inc. now owns 2,336 shares of the company’s stock worth $613,000 after acquiring an additional 93 shares during the period. Shilanski & Associates Inc. raised its position in shares of argenx by 6.6% in the 2nd quarter. Shilanski & Associates Inc. now owns 1,628 shares of the company’s stock worth $367,000 after acquiring an additional 101 shares in the last quarter. Comerica Bank lifted its stake in shares of argenx by 5.2% in the 2nd quarter. Comerica Bank now owns 2,216 shares of the company’s stock valued at $575,000 after purchasing an additional 109 shares during the period. Finally, Brinker Capital Inc. boosted its position in shares of argenx by 5.0% during the 2nd quarter. Brinker Capital Inc. now owns 2,830 shares of the company’s stock valued at $637,000 after purchasing an additional 135 shares in the last quarter. 56.98% of the stock is currently owned by institutional investors.
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis in Phase 3; immune thrombocytopenia in Phase 3; pemphigus vulgaris in Phase 2; chronic inflammatory demyelinating polyneuropathy in Phase 2; and ENHANZE SC in pre-clinical stages.
Recommended Story: How is an ETF different from a mutual fund?
Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.